×
About 13,651 results

ALLMedicine™ Hypertrophic Cardiomyopathy Center

Research & Reviews  6,701 results

Severe Cardiopulmonary Disease in a Parturient With Noonan Syndrome.
https://doi.org/10.1177/1089253220945918
Seminars in Cardiothoracic and Vascular Anesthesia; Siegrist KK, Deegan RJ et. al.

Aug 3rd, 2020 - Noonan syndrome is a relatively common genetic disorder and the second most common cause of congenital heart disease after trisomy 21. The spectrum of cardiac anomalies in Noonan syndrome typically involves pulmonary valve stenosis occasionally in...

Hypertrophic Cardiomyopathy: Is a 'Cure' Coming . . . Or Is It Already Here?
https://doi.org/10.1016/j.amjmed.2020.03.015
The American Journal of Medicine; Maron BJ, Rowin EJ et. al.

Aug 2nd, 2020 - Hypertrophic Cardiomyopathy: Is a 'Cure' Coming . . . Or Is It Already Here?|2020|Maron BJ,Rowin EJ,Maron MS,|

A case of late-detected Pheochromocytoma in a young patient with resistant hypertension...
https://doi.org/10.1093/ajh/hpaa126
American Journal of Hypertension; Alamri A, Oriez C et. al.

Aug 2nd, 2020 - A case of late-detected Pheochromocytoma in a young patient with resistant hypertension and hypertrophic cardiomyopathy.|2020|Alamri A,Oriez C,Brenier M,Voican A,Banu I,|

Matrix Metalloproteinases Increase Due to Hypoperfusion in Obstructive Hypertrophic Car...
https://doi.org/10.1016/j.athoracsur.2020.05.156
The Annals of Thoracic Surgery; Bi X, Yang C et. al.

Aug 1st, 2020 - Myocardial fibrosis (MF) is considered a result of microvascular dysfunction in patients with hypertrophic cardiomyopathy (HCM). Matrix metalloproteinases (MMPs) and their tissue inhibitors (TIMPs), capable to degrade collagen, directly participat...

Prevalence, causes and predictors of cardiovascular hospitalization in patients with hy...
https://doi.org/10.1016/j.ijcard.2020.07.036
International Journal of Cardiology; Ciabatti M, Fumagalli C et. al.

Jul 31st, 2020 - Despite numerous studies assessing the natural history of patients with hypertrophic cardiomyopathy (HCM), there is lack of data regarding the burden of hospitalization. Aim of this study was to describe prevalence, causes and predictors of cardio...

see more →

Guidelines  15 results

Enhanced American College of Cardiology/American Heart Association Strategy for Prevention of Sudden Cardiac Death in High-Risk Patients With Hypertrophic Cardiomyopathy
https://jamanetwork.com/journals/jamacardiology/fullarticle/2733139

May 21st, 2019 - Question Is it possible to identify most patients with hypertrophic cardiomyopathy (HCM) at risk of arrhythmic sudden cardiac death (SCD) and to prevent such events with prophylactic implantable cardioverter/defibrillators (ICDs)? Findings In t...

Recommendations for participation in competitive and leisure time sport in athletes wit...
https://doi.org/10.1093/eurheartj/ehy730
European Heart Journal; Pelliccia A, Solberg EE et. al.

Dec 18th, 2018 - Myocardial diseases are associated with an increased risk of potentially fatal cardiac arrhythmias and sudden cardiac death/cardiac arrest during exercise, including hypertrophic cardiomyopathy, dilated cardiomyopathy, left ventricular non-compact...

Guidelines for Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy (JC...
https://doi.org/10.1253/circj.CJ-66-0122
Circulation Journal : Official Journal of the Japanese Circulation Society;

Feb 4th, 2016 - Guidelines for Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy (JCS 2012) - Digest Version .|2016| ,|diagnosis,physiopathology,therapy,

2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Tas...
https://doi.org/10.1093/eurheartj/ehu284
European Heart Journal; , Elliott PM et. al.

Aug 31st, 2014 - 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC).|2014| ,Elliott PM,Anastasakis A,Borger MA,B...

2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy:...
https://doi.org/10.1016/j.jtcvs.2011.10.019
The Journal of Thoracic and Cardiovascular Surgery; , et. al.

Nov 18th, 2011 - 2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.|2011| , , , , ,|diag...

see more →

Clinicaltrials.gov  6,795 results

Severe Cardiopulmonary Disease in a Parturient With Noonan Syndrome.
https://doi.org/10.1177/1089253220945918
Seminars in Cardiothoracic and Vascular Anesthesia; Siegrist KK, Deegan RJ et. al.

Aug 3rd, 2020 - Noonan syndrome is a relatively common genetic disorder and the second most common cause of congenital heart disease after trisomy 21. The spectrum of cardiac anomalies in Noonan syndrome typically involves pulmonary valve stenosis occasionally in...

Hypertrophic Cardiomyopathy: Is a 'Cure' Coming . . . Or Is It Already Here?
https://doi.org/10.1016/j.amjmed.2020.03.015
The American Journal of Medicine; Maron BJ, Rowin EJ et. al.

Aug 2nd, 2020 - Hypertrophic Cardiomyopathy: Is a 'Cure' Coming . . . Or Is It Already Here?|2020|Maron BJ,Rowin EJ,Maron MS,|

A case of late-detected Pheochromocytoma in a young patient with resistant hypertension...
https://doi.org/10.1093/ajh/hpaa126
American Journal of Hypertension; Alamri A, Oriez C et. al.

Aug 2nd, 2020 - A case of late-detected Pheochromocytoma in a young patient with resistant hypertension and hypertrophic cardiomyopathy.|2020|Alamri A,Oriez C,Brenier M,Voican A,Banu I,|

Matrix Metalloproteinases Increase Due to Hypoperfusion in Obstructive Hypertrophic Car...
https://doi.org/10.1016/j.athoracsur.2020.05.156
The Annals of Thoracic Surgery; Bi X, Yang C et. al.

Aug 1st, 2020 - Myocardial fibrosis (MF) is considered a result of microvascular dysfunction in patients with hypertrophic cardiomyopathy (HCM). Matrix metalloproteinases (MMPs) and their tissue inhibitors (TIMPs), capable to degrade collagen, directly participat...

Prevalence, causes and predictors of cardiovascular hospitalization in patients with hy...
https://doi.org/10.1016/j.ijcard.2020.07.036
International Journal of Cardiology; Ciabatti M, Fumagalli C et. al.

Jul 31st, 2020 - Despite numerous studies assessing the natural history of patients with hypertrophic cardiomyopathy (HCM), there is lack of data regarding the burden of hospitalization. Aim of this study was to describe prevalence, causes and predictors of cardio...

see more →

News  105 results

Enhanced American College of Cardiology/American Heart Association Strategy for Prevention of Sudden Cardiac Death in High-Risk Patients With Hypertrophic Cardiomyopathy
https://jamanetwork.com/journals/jamacardiology/fullarticle/2733139

May 21st, 2019 - Question Is it possible to identify most patients with hypertrophic cardiomyopathy (HCM) at risk of arrhythmic sudden cardiac death (SCD) and to prevent such events with prophylactic implantable cardioverter/defibrillators (ICDs)? Findings In t...

Hydrogen for CHD Surgery? Promising Cardiomyopathy Drug; MITRA-HR Trial
https://www.medpagetoday.com/cardiology/prevention/79636

May 6th, 2019 - Patient-reported outcomes have been collected in only 14% of atrial fibrillation studies on Clinicaltrials.gov. (JACC: Clinical Electrophysiology) Novel cardiac myosin modulator mavacamten met its primary endpoint in obstructive hypertrophic cardi...

Apple Watch algorithm brings wearables closer to clinical practice
https://www.mdedge.com/familymedicine/article/196494/arrhythmias-ep/apple-watch-algorithm-brings-wearables-closer-clinical?channel=39313
MDedge Cardiology; Bruce Jancin

Mar 16th, 2019 - NEW ORLEANS – The portability, convenience, and the mobile health care that wearable technology achieve is clearly being described in the Apple Heart Study, Matthew W. Martinez, MD, medical director of the Sports Cardiology and Hypertrophic Cardio.

Physiological versus pathological cardiac remodeling in athletes
https://www.mdedge.com/internalmedicine/article/194369/imaging/physiological-versus-pathological-cardiac-remodeling?channel=39313
Bruce Jancin

Feb 12th, 2019 - SNOWMASS, COLO. – Cardiac MRI is the go-to tiebreaker when uncertainty exists as to whether cardiac remodeling in a competitive athlete is physiological or pathological, according to Matthew W.

Trimetazidine Disappoints in Non-Obstructive Cardiomyopathy
https://www.medpagetoday.com/cardiology/chf/77854

Feb 6th, 2019 - Another fatty acid β-oxidation inhibitor failed to boost exercise capacity or ease symptoms in non-obstructive hypertrophic cardiomyopathy (HCM) in a small placebo-controlled trial. Study participants who were randomized to trimetazidine had a sma...

see more →

Patient Education  35 results see all →